Overview
Dominik Loser practices practicing medicine in Reutlingen, Germany.
His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Neurotoxicity Syndromes, and Gliomatosis Cerebri.
He is actively involved in clinical research, co-authoring 8 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Dominik Loser
Is Dominik Loser a top-rated expert for Neuroblastoma?
MediFind is an objective health platform that identifies experts based on real-world data. Dominik Loser is classified as an Experienced expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Dominik Loser participate in research or clinical trials?
Yes. Dominik Loser has published 8 articles and abstracts on conditions like Neuroblastoma. You can view a list of Dominik Loser's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Embryonal Tumor with Multilayered Rosettes
- Gliomatosis CerebriMr. Loser isExperienced. Learn about Gliomatosis Cerebri.
- NeuroblastomaMr. Loser isExperienced. Learn about Neuroblastoma.
- Neurotoxicity SyndromesMr. Loser isExperienced. Learn about Neurotoxicity Syndromes.